Nasdaq atai.
Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.
NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ...- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ...How much insider buying is happening at Atai Life Sciences? Insiders have purchased a total of 1,618,685 ATAI shares in the last 24 months for a total of $3,116,715.96 bought.Atai Life Sciences (NASDAQ: ATAI) is another clinical-stage biopharmaceutical company that seeks to transform the treatment of mental health conditions using innovative psychedelic-based drugs ...
On the other hand, atai (NASDAQ:ATAI)’s Phase 1 clinical trial testing atypical opioid receptor modulator KUR-101 towards Opioid Use Disorder treatment has provided mixed results, which seem to ...Atai Life Sciences (NASDAQ:ATAI) is one of the leading biotech companies discovering and developing treatments derived from psychedelic compounds. Atai already has an MDMA-derived drug in its ...
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.
Find the latest SEC Filings data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. ... ATAI Life Sciences NV (NASDAQ:ATAI) 1.07. Delayed Data. As of 3:58pm ET -0.055 ...ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.
Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market ...
Mar 31, 2023 · In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. ... NASDAQ: ATAI Atai Life Sciences. Market Cap. $173M. Today's Change (-7.14% ...
atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.For ATAI Life Sciences NV (NASDAQ:ATAI), Canaccord Genuity initiated coverage, by setting the current rating at Buy. The stock has a 52-week-high of $22.91 and a 52-week-low of $16.50.Alcohol use disorder. Treatment-resistant depression. Opiate withdrawal syndrome. PTSD. Social anxiety in autistic adults. Anxiety with a life-threatening illness. Generalized anxiety disorder ...Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. ... ATAI Life Sciences NV (NASDAQ:ATAI) 1.07. Delayed Data. As of 3:58pm ET -0.055 ...Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.DemeRx, a subsidiary of Atai Life Sciences (NASDAQ: ATAI), is developing psychedelic ibogaine for the treatment of opioid use disorder and just announced it has begun a phase 1/2a clinical trial on healthy volunteers and recreational drug users. Ibogaine is a dissociative psychoactive compound naturally found in the iboga tree, which is a …
We are currently testing DMX-1002, atai’s oral formulation of ibogaine, in an ongoing Phase 1/2 trial to evaluate its safety, tolerability, pharmacokinetics, and efficacy. We expect initial data ...atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101. - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics ...111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed …Atai Life Sciences (NASDAQ:ATAI) has a recorded annual revenue of $230,000.00. How much profit does Atai Life Sciences generate each year? Atai Life Sciences (NASDAQ:ATAI) has a recorded net income of -$152.38 million.Find the latest Earnings Report Date for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside potential of 969% from ...
(Part four of a four-part series) See previous stories in this series: Insider's Peek At Mammoth Of Psychedelics VCs, Palo S...ATAI Life Sciences N.V. Common Shares (ATAI) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.
Creso Pharma and Red Light Holland entered into a definitive scheme implementation deed to combine businesses and create The HighBrid LabOver the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Sep 1, 2023 · DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ... On March 30, atai Life Sciences N.V. (NASDAQ: ATAI) reported fourth-quarter and full-year 2021 financial results and R&D progress. The clinical-stage biopharma company also highlighted strategic ...Nov 29, 2023 · 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.
Therefore, something I will be watching closely is whether companies like MindMed, Compass, and atai Life Sciences (NASDAQ:ATAI) can win back some of their lost market caps.
4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the …
Find the latest analyst research for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated coverage of ATAI Life Sciences N.V. (NASDAQ:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 605.71% Upside. As ...On September 13, 2023, Florian Brand, See Remarks at ATAI Life Sciences NV (NASDAQ:ATAI), made a significant purchase of 40,000 shares of the company's stock. Benzinga.Nov 15, 2021 · The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ... Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ... Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...Atai Capital highlighted stocks like Alphabet Inc. (NASDAQ:GOOG) in the Q3 2023 investor letter. Headquartered in Mountain View, California, Alphabet Inc. …4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the …Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights ...
ATAI Life Sciences N.V. (NASDAQ:ATAI)’s traded shares stood at 0.58 million during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $1.32, to imply an increase of 6.45% or $0.08 in intraday trading. The ATAI share’s 52-week high ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...Nov 21, 2023 · Atai Life Sciences The Trade : Atai Life Sciences N.V. (NASDAQ:ATAI) Florian Brand acquired a total of 20,000 shares at an average price of $1.16. The insider spent around $23,120 to buy those shares. Instagram:https://instagram. most expensive house in dallaswhere to buy twitter stockbest dental insurance in njfund management course Dec 2, 2023 · The latest price target for ATAI Life Sciences ( NASDAQ: ATAI) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 20.00 expecting ATAI to rise ... lucid stock predictionis options trading profitable DemeRx, a subsidiary of Atai Life Sciences (NASDAQ: ATAI), is developing psychedelic ibogaine for the treatment of opioid use disorder and just announced it has begun a phase 1/2a clinical trial on healthy volunteers and recreational drug users. Ibogaine is a dissociative psychoactive compound naturally found in the iboga tree, which is a …Find the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. amba stock symbol -5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...4 days ago ... Atai Life Sciences N.V.'s stock symbol is ATAI and currently trades under NASDAQ. It's current price per share is approximately $1.12. How much ...